BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15289305)

  • 1. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
    Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
    Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
    Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
    Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A; Northcote PT; Miller JH
    Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
    Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
    Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.
    Hamel E; Day BW; Miller JH; Jung MK; Northcote PT; Ghosh AK; Curran DP; Cushman M; Nicolaou KC; Paterson I; Sorensen EJ
    Mol Pharmacol; 2006 Nov; 70(5):1555-64. PubMed ID: 16887932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
    Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
    Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
    Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique mode of microtubule stabilization induced by peloruside A.
    Huzil JT; Chik JK; Slysz GW; Freedman H; Tuszynski J; Taylor RE; Sackett DL; Schriemer DC
    J Mol Biol; 2008 May; 378(5):1016-30. PubMed ID: 18405918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of microtubule stabilization by laulimalide and peloruside A.
    Prota AE; Bargsten K; Northcote PT; Marsh M; Altmann KH; Miller JH; Díaz JF; Steinmetz MO
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1621-5. PubMed ID: 24470331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
    Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
    Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.
    Das V; Miller JH
    Brain Res; 2012 Dec; 1489():121-32. PubMed ID: 23085090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
    Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration.
    Field JJ; Northcote PT; Paterson I; Altmann KH; Díaz JF; Miller JH
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.
    Nguyen TL; Xu X; Gussio R; Ghosh AK; Hamel E
    J Chem Inf Model; 2010 Nov; 50(11):2019-28. PubMed ID: 21028850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical genetic profiling of the microtubule-targeting agent peloruside A in budding yeast Saccharomyces cerevisiae.
    Wilmes A; Hanna R; Heathcott RW; Northcote PT; Atkinson PH; Bellows DS; Miller JH
    Gene; 2012 Apr; 497(2):140-6. PubMed ID: 22326528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
    Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
    Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
    Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
    Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.
    Pryor DE; O'Brate A; Bilcer G; Díaz JF; Wang Y; Wang Y; Kabaki M; Jung MK; Andreu JM; Ghosh AK; Giannakakou P; Hamel E
    Biochemistry; 2002 Jul; 41(29):9109-15. PubMed ID: 12119025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laulimalide and peloruside A inhibit mitosis of Saccharomyces cerevisiae by preventing microtubule depolymerisation-dependent steps in chromosome separation and nuclear positioning.
    Best HA; Matthews JH; Heathcott RW; Hanna R; Leahy DC; Coorey NV; Bellows DS; Atkinson PH; Miller JH
    Mol Biosyst; 2013 Nov; 9(11):2842-52. PubMed ID: 24056987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.